Upload
nguyenkiet
View
236
Download
9
Embed Size (px)
Citation preview
1
(Evidence-based treatment of UTI)
2
(Evidence-based clinical practice guideline)
2002)
3
(infection)
-
-
-
-
-
-
-
-
-
-
-
4
(urinary tract infectionUTI)
(inflammatory response)
Anthony J Schaeffer : Infections of the Urinary Tract in Campbells Urology, 7th ed, 1998
5
Acute cystitis in women
E-coli, staphylococcus saprophyticus, proteus mirabilis, klebsiella pneumoniae
Sexual history, personal hygeine. use of diaphragm, pregnancy, symptoms > 7 days
Acute pyelonephritis in women
E-coli, Proteus mirabilis, staphylococcus saprophyticus, klebsiella pneumoniae
Sexual history, pregnancy,DM, foley catheter, children, age > 65 y/o, neurogenic bladder, renal stone,
UTI in man
E-coli, Proteus, Klebsiela, Pseudomonas, enterococcus, staphylococcus
Sexual history,BPH, DM, foley catheter, children, age > 65 y/o, neurogenic bladder, renal stone,
6
(bacteriuria)
()
(pyuria)
(white blood cell)
(urinary tract infection)
Anthony J Schaeffer : Infections of the Urinary Tract in Campbells Urology, 7th ed, 1998
7
Urine culture and bacteriuria
Urine culture(cfu/ml)
Asymptomatic bacteriuria >= 100,000
Pyelonephritis >=10,000
Cystitis >=1,000
8
()
9
()
uncomplicated UTI
cystitis
urethritis
complicated UTI
acute pyelonephritis
chronic pyelonephritis
renal abscess or carbuncle
Urinary tract infection with host structural or immune abnormality.
Male with urinary tract infection
reinfection (another episode)
bacterial persistence (same bacteria, not eradicated)
10
trimethoprim-sulfamethoxazole (TMP-SMX, Baktar)
cephalosporins
fluoroquinolones
aminoglycosides
nitrofurantoin
aminopenicillins
aztreonam
Anthony J Schaeffer : Infections of the Urinary Tract in Campbells Urology, 7th ed, 1998
11
Evidence-Based Clinical Practice Guideline
12
?
David L. Sackett et al. (Ontario, Canada, 2000)
:
Evidence-based medicine (EBM) is the integration of best research evidence with clinical expertise and patient values.-
,
,.
13
, (),
.
14
Systematic review of randomized control studies
Single randomized control study
Systematic review of observational studies
Single observational study
Physiologic studies
Unsystematic clinical observationslow
high
Hierarchy of evidence
Guyatt et al. 2002
( less bias )
( more bias )
15
? (systematic review)
,
, ,, .
Systematic reviews are scientific investigations in themselves, with pre-planned methods and an assembly of original studies as their subjects. They synthesize the results of multiple primary investigations by using strategies that limit bias and random error.
Mulrow & Cook, in Systematic Reviews - synthesis of best evidence for health care decisions, 1998, American College of Physicians.
16
National Guideline Clearinghouse
National Guideline Clearinghouse
Guideline
?
National Guideline Clearinghouse (www.guideline.gov)
http://www.guideline.gov/
17
National Guideline Clearinghouse
Evidence-based clinical practice guidelines for patients 6 years of age or less with first time acute urinary tract infection.
( Childrens Hospital Medical Center, Cincinnati ,1999)
Guidelines for Antimicrobial Treatment of Uncomplicated Acute Bacterial Cystitis and Acute Pyelonephritis in Women
(Infectious Disease Society of America, IDSA 1999)
Use of antibiotics in adults(Singapore Ministry of Health, MOH, 2000)
!
18
(presumed UTI)
Presumed UTI = UTI symptoms + abnormal urinalysis (pyuria)
abnormal urinalysis
(nitrite)
esterase
(microscopic exam)
19
(definite UTI)
+
Definite UTI=presumed UTI
+ positive urine cultutre
(single
organism)
suprapubic aspirate (SPA) >= 1,000 cfu/ml
catheter specimen (Cath)>=10,000 cfu/ml
clean voided specimen ( CVS)>=100,000 cfu/ml
20
(Uncomplicated UTI)
,
21
(Complicated UTI)
(VU reflux in children)
(neurogenic bladder, BPH, stone, stricture or tumor)
22
(uncomplicated acute bacterial cystitis)
3
(dysuria)
(frequency)
(urgency)
>1,000 cfu/ml
23
(acute pyelonephritis)
(fever), / (flank pain)
3 (dysuria)(frequency)
(urgency)
( )
24
Recommended treatment for uncomplicated and complicated UTI
A( Ia Ib)
(literature of good quality) (randomised, controlled trial)
B( IIa IIbIII)
C( IV)
GPP (Good practice point)
(guideline development group)
Ia (randomised, controlled trials)(meta-analysis)
Ib (randomised, controlled trial)
IIa (well-designed controlled study without
randomisation)IIb
(well-designed quasi-experimental study)III (non-
experimental descriptive studies)
IV
27
(asymptomatic bacteriuria)
(A, Ib)
-
28
(acute cystitis in women)
,
(A, Ia)
:
trimethoprim/sulfamethoxazol 160/800 mg BID for 3 days (A, Ib)
fluoroquinolones (ciprofloxacin 250mgofloxacin 200mgnorfloxacin 400mg)TID
for 3 days (A, Ib)
first or second generation of cephalosporins for 7 days (B, II)
nitrofurantointrimethoprim for 7 days (B, II)
29
(recurrent cystitis in women)
trimethoprim/sulfamethoxazol 40/200 mg
nitrofurantoin 50 mg
cephalexin 100 mg
trimethoprim 100 mg
(B, IIa)
30
() (acute pyelonephritis in women)
cephalosporins
- cephalexin 250 mg qidcefaroxil 500 mg bidcefuroxime 125 mg bid
fluoroquinolones- ciprofloxacin 500 mg bidofloxacin 400 mg bidnorfloxacin 400 mg bid
amoxicillin-clavulanic acid 375 mg tid
trimethoprim/sulfamethoxazol 160/800 mg bid
(14) (B, III)
31
() (acute pyelonephritis in women)
()!
:
- cephalosporins- fluoroquinolones- ampicillins plus aminoglycosides- cephalosporins plus aminoglycosides (B,III)
cephalosporins plus aminoglycosides cephazolin 500 mg q8h or cefuroxime 750 mg q8h
+ gentamicin 1 mg/kg q8h
24
(14)
(B, III)
32
(UTI in pregnancy)
(asymptomatic bacteriuria)
(A, Ia)
(acute cystitis) cephalosporins
nitrofurantointrimethoprim/sulfamethoxazole
(7)
(B, III)
(acute pyelonephritis in pregnancy) cephalosporins
(ceftriaxone 1 g)
(14)
(B, III)
33
(acute cystitis in adult men)
/
(STD)
trimethoprim/sulfamethoxazol 160/800 mg bid
fluoroquinolones
ciprofloxacin 250mgofloxacin 200mg norfloxacin 400mg bid
~ (7~14)
(C, IV)
34
(acute prostatitis)
,,
(blood PSA,
urine or prostate secretion culture)
trimethoprim/sulfamethoxazol 160/800 mg bid
fluoroquinolones
ciprofloxacin 250mgofloxacin 200mg norfloxacin 400mgbid
(28)
(B, III)
35
(chronic bacterial prostatitis)
,
, ,
,
trimethoprim/sulfamethoxazol 160/800 mg bid
fluoroquinolones
ciprofloxacin 250mgofloxacin 200mg norfloxacin 400mgbid
(84)
(B, III)
36
(chronic abacterial prostatitis)
doxycyclin 100 mg bid
erythromycin 250mg qid
(14)
(C, IV)
37
(complicated UTI)
fluoroquinolones
trimethoprim/sulfamethoxazol
(14) (A, Ib)
cephalosporins
(14) (C, IV)
38
(complicated UTI)
cephalosporinsfluoroquinolones
-lactam/
-lactamase inhibitor
(14
)
(C, IV)
ampicillinaminoglycoside
(14 )
(C, IV)
39
(complicated UTI)
(catheter-related UTI, bacteriuria 10~15%, UTI 3~5% per day of catheterization)
()
(14 ~ 28)
(UTI in renal failure) aminoglycoside()
(14 ~ 42)
40
2002
41
19976-
40
34.6
12.0
10.5
7.5
5.4
---
5.1
3.9
3.1
1.8
1.8
(,1998)
42
43
(2002)
(1993)
( Mainous1998)
44
45
()
2002
12
46
()
National Guideline Clearinghouse (www.guideline.gov)
1999
2000
http://www.guideline.gov/
47
WHO
48
/
(over use)
(under use)
1.2.3.1.
-*
1.
2.
*(clinical practice guidelines)
50
A. 200,000B. 2,572,065C. a. 11,008 (a/A = 5.5%)b. 26,129 (b/B = 1.02%)
2.37/ (b/a)c. 134,051 5.13/(c/b)
d. () 2.71e. 13,255 (e/c = 13.41)
Fluoroquinolone 2,817 31.92Nitrofurantoin 1,537 17.42Cephalosporin 4,138 46.89
Trimethoprim - Sulfamethoxazole 333 3.77
8,825 100.00
under use appropriate over use Total
Fluoroquinolone 367(13.03) 1,828(64.89) 622(22.08) 2,817(100)
Nitrofurantoin 1,343(87.38) 128(8.33) 66(4.29) 1,537(100)
Cephalosporin 739(17.86) 3,209(77.55) 190(4.59) 4,138(100)
Trimethoprim - Sulfamethoxazole 13(3.90) 135(40.54) 185(55.56) 333(100)
4,264(27.90) 5,300(60.06) 1,063(12.05) 8,825(100)
Fluoroquinolone 39 16.88Cephalosporin 138 59.74
Amoxicillin - Clavulanic acid 38 16.45
Trimethoprim - Sulfamethoxazole
16 6.93
231 100.00
under use appropriate over use Total
Fluoroquinolone 21(53.85) 16(41.02) 2(5.13) 39(100)
Amoxicillin - Clavulanic acid 7(18.42) 19(50.00) 12(31.58) 38(100)
Cephalosporin 81(58.7) 55(39.85) 2(1.45) 138(100)
Trimethoprim - Sulfamethoxazole 4(25.00) 2(12.50) 10(62.50) 16(100)
113(48.92) 92(39.83) 26(11.26) 231(100)
()
Odds ratio95
-0.8606 0.1238
(12~20)
21-40 -0.0279 0.1110 0.972 0.782~1.209
41-60 0.2641 0.1108 1.302* 1.048~1.618
>60 0.4064 0.1154 1.501** 1.197~1.882
()
-0.1231 0.0727 0.884 0.767~1.020
-0.2781 0.0652 0.757 *** 0.666~0.860
-0.0317 0.0725 1.311 0.959~1.792
0.0472 0.0654 1.048 0.922~1.192
-0.5769 0.1570 0.562** 0.413~0.760
()
0.3721 0.1797 1.451* 1.020~2.064
0.4524 0.1861 1.572* 1.092~2.264
0.2788 0.1718 1.322 0.944~1.851
*P
()
Odds Ratio95
()
0.3017 0.1907 1.352 0.930~1.965
0.1584 0.1799 1.172 0.823~1.667
-0.1549 0.1798 0.857 0.602~1.219
()
-0.3209 0.0969 0.725** 0.600~0.877
0.2282 0.0918 1.256* 1.050~1.504
0.2706 0.1595 1.311 0.959~1.792
-0.5851 0.2594 0.557* 0.335~0.926
0.4765 0.0698 1.610*** 1.405~1.846
-0.1544 0.0933 0.857 0.714~1.029
-0.2116 0.1727 0.809 0.577~1.135
-0.4607 0.1836 0.631* 0.440~0.904
-0.4107 0.3314 0.663 0.346~1.270#-2Log Likelihood=11575.1522=299.4373, DF=23(P
()
*P
()
*P
60
()--FluoroquinoloneNitrofurantoinCephalosporin
Trimethoprim Sulfamethoxazole
60.06
27.912.05
cephalosporin46.89% 22.45%
Trimethoprim Sulfamethoxazole3.77% 59.46%
Nitrofurantoin17.42% 91.67%
87.38%
61
()--
62
()--FluoroquinoloneCephalosporin Amoxicilli Clavulanic acidTrimethoprim Sulfamethoxazole
48.92
39.8311.26
cephalosporin59.74%
60.15% 58.7%
Trimethoprim
Sulfamethoxazole
6.93% 87.5%
63
()--
(Evidence-based treatment of UTI)(infection)(urinary tract infectionUTI)Urine culture and bacteriuria()() ? ?(systematic review)National Guideline Clearinghouse National Guideline Clearinghouse(presumed UTI)(definite UTI)(Uncomplicated UTI) (Complicated UTI) (uncomplicated acute bacterial cystitis)(acute pyelonephritis) 25 26 (asymptomatic bacteriuria)(acute cystitis in women) (recurrent cystitis in women)()(acute pyelonephritis in women)()(acute pyelonephritis in women) (UTI in pregnancy)(acute cystitis in adult men) (acute prostatitis) (chronic bacterial prostatitis) (chronic abacterial prostatitis) (complicated UTI)(complicated UTI)(complicated UTI) () ()/ ()()()()()--()--()--()-- 64